Simona Pagliuca

List of Publications by Year
in descending order

57	428	933447	839539
papers	citations	10 h-index	18 g-index

58	58	58	638
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Advances, 2022, 6, 100-107.	5.2	12
2	Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. Journal of Clinical Investigation, 2022, 132, .	8.2	15
3	A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia. Hematological Oncology, 2022, , .	1.7	3
4	Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes. International Journal of Molecular Sciences, 2022, 23, 2802.	4.1	10
5	Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms. Leukemia, 2022, 36, 2086-2096.	7.2	2
6	Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. Haematologica, 2021, 106, 2374-2383.	3.5	14
7	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 38-49.	2.4	9
8	Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. Blood Cells, Molecules, and Diseases, 2021, 87, 102528.	1.4	8
9	A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenaseâ€“Deficient Cells in Myeloid Neoplasms. Blood Cancer Discovery, 2021, 2, 146-161.	5.0	36
10	Novel invariant features of Good syndrome. Leukemia, 2021, 35, 1792-1796.	7.2	11
11	Point-of-care ultrasound with handheld devices in hematology: a monocentric single-stage phase II study. Leukemia and Lymphoma, 2021, 62, 1379-1385.	1.3	0
12	Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments. Cancers, 2021, 13, 784.	3.7	14
13	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. Leukemia, 2021, 35, 3324-3328.	7.2	2
14	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood, 2021, 137, 3685-3689.	1.4	50
15	The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies. International Journal of Molecular Sciences, 2021, 22, 3135.	4.1	5
16	Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia. Blood Cells, Molecules, and Diseases, 2021, 88, 102549.	1.4	1
17	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. JCI Insight, 2021, 6, .	5.0	12
18	A nonâ€cytotoxic regimen of decitabine to treat refractory Tâ€cell large granular lymphocytic leukemia. Clinical Case Reports (discontinued), 2021, 9, e04533.	0.5	3

#	Article	IF	Citations
19	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. Blood Cells, Molecules, and Diseases, 2021, 91, 102595.	1.4	2
20	Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. Leukemia, 2021, 35, 2431-2434.	7.2	10
21	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. Blood, 2021, 138, 2781-2798.	1.4	27
22	Immunogenetic, Molecular and Clinical Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2021, 138, 602-602.	1.4	1
23	Epigenetic Enzyme Mutations in Myeloid Malignancies Are Selected By Chromatin-Remodeling Requirements That Vary By Lineage- and Maturation-Stage. Blood, 2021, 138, 1148-1148.	1.4	3
24	A Novel Machine Learning-Derived Molecular Classification Scheme with Prognostic Significance. Blood, 2021, 138, 3666-3666.	1.4	1
25	Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. Blood Cancer Journal, 2021, 11, 187.	6.2	11
26	Is Nature Truly Healing Itself? Spontaneous Remissions and Clonal Replacement in Paroxysmal Nocturnal Hemoglobinuria. Blood, 2021, 138, 4303-4303.	1.4	0
27	Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. Leukemia, 2021, , .	7.2	1
28	Spectrum of Molecular Modes of Immune Escape in Idiopathic Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2021, 138, 603-603.	1.4	1
29	Molecular Signatures of Immune Pressure and Immune Escape in Hematological Malignancies. Blood, 2021, 138, 1093-1093.	1.4	0
30	Transcriptomic Profile Identifies Early Signatures of Immunoediting and a Potential Role for VISTA As a Molecular Target in Acute Myeloid Leukemia. Blood, 2021, 138, 4467-4467.	1.4	1
31	Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1343-1351.	2.0	2
32	Alternative Splicing in Myeloid Malignancies. Biomedicines, 2021, 9, 1844.	3.2	5
33	A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor. Bone Marrow Transplantation, 2020, 55, 86-92.	2.4	9
34	Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2020, 21, 8505.	4.1	12
35	Human-Derived Î±1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 1620-1626.	2.0	10
36	Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report. Annals of Hematology, 2020, 99, 897-898.	1.8	1

#	Article	IF	Citations
37	The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia. Blood, 2020, 136, 8-8.	1.4	1
38	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. Blood, 2020, 136, 2-2.	1.4	1
39	Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia. Blood, 2020, 136, 1-1.	1.4	1
40	Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles. Blood, 2020, 136, 25-25.	1.4	0
41	Immunogenomics of Paroxysmal Nocturnal Hemoglobinuria: A Model of Immune Escape. Blood, 2020, 136, 21-22.	1.4	0
42	Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2020, 136, 2-3.	1.4	0
43	Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms. Blood, 2020, 136, 28-28.	1.4	0
44	The Genomic Landscape of Wilms' Tumor 1 (WT1) Mutant Acute Myeloid Leukemia. Blood, 2020, 136, 28-28.	1.4	1
45	Implication of Piga Genotype on Clinical Features of PNH. Blood, 2020, 136, 34-35.	1.4	0
46	Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia. Blood, 2020, 136, 34-35.	1.4	0
47	Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence. Blood, 2020, 136, 20-21.	1.4	0
48	Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA. Blood, 2020, 136, 2-3.	1.4	0
49	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. Blood, 2020, 136, 21-21.	1.4	0
50	Comparative Genomic Analysis of Adolescents and Young Adults Versus Elderly with Acute Myeloid Leukemia. Blood, 2020, 136, 18-18.	1.4	0
51	Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2490-2500.	2.0	9
52	Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2018. Leukemia Research, 2019, 80, 19-25.	0.8	1
53	Allogeneic reactivityâ€“mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Advances, 2019, 3, 2424-2435.	5.2	66
54	Cord blood transplantation for bone marrow failure syndromes: state of art. Stem Cell Investigation, 2019, 6, 39-39.	3.0	8

#	Article	IF	Citations
55	Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1939-1948.	2.0	19
56	Success of haploidentical hematopoietic stem cells transplantation in the treatment of graft failure. Annals of Hematology, 2016, 95, 353-354.	1.8	2
57	Evaluation of Graft Versus Host Disease and Relapse Free Survival As Novel Endpoint in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Joint Naples-Paris Study. Blood, 2016, 128, 2285-2285.	1.4	15